Cancer drug doses put to the test in healthy volunteers

NCT ID NCT05391048

Completed Knowledge-focused Sponsor: Impact Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested two different strengths (10 mg and 20 mg) of an experimental drug called IMP4297 in 36 healthy Chinese men. The goal was to see if the two strengths are processed the same way in the body after a meal. This is a bioequivalence study, meaning it checks if different doses give the same drug levels in the blood. The results will help decide which strength to use in future studies for solid tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IMP4297 (a drug being tested for solid tumors)
What this could lead to: If successful, this study could confirm that both capsule strengths deliver the same amount of drug, supporting future trials for solid tumor treatment.
What could go wrong: This is a very early, small study in healthy people, not patients. It only checks how the drug is processed, not if it works against cancer. Results may not predict effectiveness or safety in patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Xuzhou Central Hospital

Xuzhou, Jiangsu, 221000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.